
A Phase 2 placebo controlled dose ranging medical study in pediatric patients with EoE conducted by Meritage enrolled 82 patients with 71 completing therapy. Meritage evaluated OBS treatment by assessing histologic response (specifically the extent of esophageal eosinophilia) and clinical symptoms. Analyses on the compound primary endpoint, histologic response and decrease in symptoms, showed a statistically significant response around the histological component inside medium as well as dose groups in comparison with placebo.
gain consciousness. Have to imagine that the temperature inside the wheel well wasn around minus 40 degrees, says Honigman.